Journal of Neuroimmune Pharmacology ( IF 5.2 ) Pub Date : 2021-01-06 , DOI: 10.1007/s11481-020-09968-x Bhavesh D Kevadiya 1 , Jatin Machhi 1 , Jonathan Herskovitz 1, 2 , Maxim D Oleynikov 1 , Wilson R Blomberg 1 , Neha Bajwa 3 , Dhruvkumar Soni 4 , Srijanee Das 1, 2 , Mahmudul Hasan 4 , Milankumar Patel 1 , Ahmed M Senan 5 , Santhi Gorantla 1 , JoEllyn McMillan 1 , Benson Edagwa 1 , Robert Eisenberg 6 , Channabasavaiah B Gurumurthy 1 , St Patrick M Reid 2 , Chamindie Punyadeera 7 , Linda Chang 8 , Howard E Gendelman 1, 2, 4
|
The COVID-19 pandemic has affected more than 38 million people world-wide by person to person transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Therapeutic and preventative strategies for SARS-CoV-2 remains a significant challenge. Within the past several months, effective treatment options have emerged and now include repurposed antivirals, corticosteroids and virus-specific antibodies. The latter has included convalescence plasma and monoclonal antibodies. Complete viral eradication will be achieved through an effective, safe and preventative vaccine. To now provide a comprehensive summary for each of the pharmacotherapeutics and preventative strategies being offered or soon to be developed for SARS-CoV-2.
Graphical abstract
中文翻译：
SARS-CoV-2 感染的药物治疗
COVID-19 大流行已通过严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的人际传播影响了全球超过 3800 万人。 SARS-CoV-2 的治疗和预防策略仍然是一个重大挑战。在过去的几个月里，有效的治疗方案已经出现，其中包括重新调整用途的抗病毒药物、皮质类固醇和病毒特异性抗体。后者包括恢复期血浆和单克隆抗体。通过有效、安全和预防性的疫苗将实现彻底消灭病毒。现在对针对 SARS-CoV-2 正在提供或即将开发的每种药物治疗和预防策略进行全面总结。
京公网安备 11010802027423号